ChronoScale's Scott Davis resigns from board after Ekso sale; receives RSUs and $709,500 payment

ChronoScale announced Scott Davis's resignation from its board, effective October 3, 2026, following the sale of its subsidiary Ekso. Davis, who served as Ekso's CEO, received 51,626 fully vested RSUs and a $709,500 lump-sum payment. The resignation was part of a release agreement, with no changes to his Phantom Performance-Based RSU Agreement.

Original reporting
Published Oct 6, 2026, 9:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 9:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ChronoScale's Scott Davis resigns from board after Ekso sale; receives RSUs and $709,500 payment — source image
Decision brief

The 30-second read

$CHRNBearishLow
01

Why it matters

The filing provides the first public details of the leadership change and associated payout, offering a modest new data point for investors.

02

Market read

Primary SEC disclosure of a board resignation with a cash payment; limited immediate market impact.

03

What to watch

Potential hidden strategic reasons for the resignation that may affect future operations.

Relevance 5/10Novelty 5/10Timing: Oct 6, 2026 (same‑day filing)

Background

ChronoScale Holdings Corp (CHRN) filed an 8‑K reporting the resignation of board member Scott Davis, who also served as CEO of its subsidiary Ekso, and disclosed a cash severance payment.

Company-level read

Ticker impact

$CHRNBearishMedium confidence
Context

ChronoScale disclosed board member Scott Davis resigned and received a $709,500 lump‑sum payment in an 8‑K filing.

Expected impact

likely slight downward pressure as investors assess the leadership change and payout.

Evidence & confidence

The news is a primary SEC filing but involves a relatively small cash amount and no strategic shift, limiting material impact.

Market effects

Minimal effect on the broader SPAC or technology sector.

Limited to U.S. investors holding CHRN.

None

Counterpoint

The resignation could be seen as a routine governance update with no real impact on valuation.

Key entities

  • ChronoScale Holdings Corp

    Public SPAC filing the 8‑K.

  • Scott Davis

    Board member and former CEO of Ekso, resigning with severance.

Related articles

$SLNHMed

Soluna and Applied Digital to build 50 MW wind-powered AI data center in Texas

Soluna (SLNH) and Applied Digital (APLD) agreed to form a joint venture to build a 50 MW wind-powered AI data center in Texas. Applied will own 51%, providing capital, while Soluna contributes land and power assets. ChronoScale (CHRN), majority-owned by Applied, may lease the facility. The project is expected to close by year-end, with Phase 1 powered by Soluna's Briscoe Wind Farm and the grid.

$CHRNMedAI 8/10

ChronoScale Reports Fiscal First Quarter 2027 Results

ChronoScale Holdings Corp (CHRN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ChronoScale Reports Fiscal First Quarter 2027 Results MENLO PARK, Calif. – October 15, 2026 — ChronoScale Holdings Corporation (NASDAQ: CHRN) (“ChronoScale” or the “Company”), an accelerated compute platform purpose-built to support demanding artificial intelligence

$CHRNMed

ChronoScale Expands AI Pipeline With $1 Billion Revenue Run Rate In Sight

ChronoScale Holdings (CHRN) shares rose after expanding AI infrastructure contracts, projecting a $1 billion annualized revenue run rate by Q3 2027. The company also completed the sale of its Ekso Bionics business. CHRN is trading at $20.33, above its 20-day and 100-day SMAs but below the 50-day SMA. Analysts rate CHRN as Strong Buy with an average price target of $32.

$CHRNHighAI 8/10

ChronoScale stock jumps on $1B revenue target from AI deals

ChronoScale Corp (CHRN) shares rose 3% after-hours after announcing deals expected to reach $1B annualized revenue run rate by Q3 2027. The AI infrastructure provider signed a contract extension and new customer agreement, though revenue is subject to deployment and capital risks. The company also sold its Ekso Bionics unit to focus on core AI infrastructure business.